Patents by Inventor Mari Carmen LARA CASTILLO

Mari Carmen LARA CASTILLO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY FOR TREATING CANCER
    Publication number: 20230122940
    Abstract: The invention relates to a combination comprising an antineoplastic agent, e.g. an antimetabolite antineoplastic agent and a type 1 serotonin receptor (HTR 1)modulator, e.g. a HTR1 antagonist. In addition the invention relates to a pharmaceutical composition comprising a combination of the invention and a pharmaceutically acceptable excipient. The invention also relates to the combination and pharmaceutical composition according to the invention for use in medicine, particularly for use in the prevention and/or treatment of a hematological malignancy.
    Type: Application
    Filed: August 10, 2022
    Publication date: April 20, 2023
    Applicant: LEUKOS BIOTECH, S.L.
    Inventors: Ruth MUÑOZ RISUEÑO, Mari Carmen LARA CASTILLO, Amaia ETXABE ALBERDI
  • Combination therapy for treating cancer
    Patent number: 11446321
    Abstract: The invention relates to a combination comprising an antineoplastic agent, e.g. an antimetabolite antineoplastic agent and a type 1 serotonin receptor (HTR1) modulator, e.g. a HTR1 antagonist. In addition the invention relates to a pharmaceutical composition comprising a combination of the invention and a pharmaceutically acceptable excipient. The invention also relates to the combination and pharmaceutical composition according to the invention for use in medicine, particularly for use in the prevention and/or treatment of a hematological malignancy.
    Type: Grant
    Filed: January 15, 2018
    Date of Patent: September 20, 2022
    Assignee: Leukos Biotech, S.L.
    Inventors: Ruth Muñoz Risueño, Mari Carmen Lara Castillo, Amaia Etxabe Alberdi
  • Combination Therapy For Treating Cancer
    Publication number: 20190365792
    Abstract: The invention relates to a combination comprising an antineoplastic agent, e.g. an antimetabolite antineoplastic agent and a type 1 serotonin receptor (HTR1) modulator, e.g. a HTR1 antagonist. In addition the invention relates to a pharmaceutical composition comprising a combination of the invention and a pharmaceutically acceptable excipient. The invention also relates to the combination and pharmaceutical composition according to the invention for use in medicine, particularly for use in the prevention and/or treatment of a hematological malignancy.
    Type: Application
    Filed: January 15, 2018
    Publication date: December 5, 2019
    Applicant: Leukos Biotech, S.L.
    Inventors: Ruth MUÑOZ RISUEÑO, Mari Carmen LARA CASTILLO, Amaia ETXABE ALBERDI